RxDoctor Payments Data

Robert Brodell, MD

Dermatology · Jackson, MSNPI 1598765943

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $15,860 of the $25,755 with a category attached, or 61.6%. 31 manufacturers reported payments, led by Regeneron at 32.1% of the total. 2025 is the largest year on record at $9,559, 2.9 times the $3,314 reported in 2019.

$25,755in general payments, 2019–2025

Across 317 payments — averaging $81.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$8K
  • Dermavant Sciences, Inc.$5K
  • Amgen$2K
  • UCB, Inc.$2K
  • Novartis$2K
  • AbbVie$1K
  • plus $5K from 25 others
$26,218in research payments, 2019–2025

Across 10 payments — averaging $2621.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$19K
  • AbbVie$4K
  • Novartis$3K

What the payments were for

  • Consulting fees$15,86062%
  • Travel & lodging$9954%
  • Food & beverage$8,80834%
  • Education$920%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,755 in reported general payments places this provider in the 85th percentile of 78 dermatology providers in Mississippi.

See all dermatology providers in Mississippi

Medicare billing

Part B allowed, 2024
$109,585
Medicare patients
1,079
Services billed
2,509

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab12$123,984
OtezlaApremilast25$113,984
Dupixent PenDupilumab21$82,025
Ketoconazole269$5,133
Clobetasol Propionate104$4,680
Triamcinolone Acetonide138$2,653
Clindamycin Phosphate51$2,462
Ciclopirox21$1,521
Betamethasone Dipropionate16$903
Hydrocortisone54$752
Doxycycline Hyclate26$663
Fluocinonide12$537
Hydroxyzine Hcl48$434
Ammonium Lactate14$424
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc11$423

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$2,368$113,98425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 78 dermatology providers in Mississippi.

Other dermatology in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →